By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ablynx 

Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


SEARCH JOBS








Company News
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014 7:23:45 AM
Additional Clinical Data From The Phase 2 Study With Ablynx (ABLYF)'s Anti-vWF Nanobody, Caplacizumab, Presented At The American Society of Hematology Annual Meeting 12/8/2014 8:17:33 AM
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014 10:14:27 AM
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 11/26/2014 2:17:50 PM
Ablynx (ABLYF) Appoints Johan Heylen As Chief Commercial Officer 11/18/2014 4:26:58 PM
Ablynx (ABLYF) To Present At The Jefferies and Co. 2014 Global Healthcare Conference In London 11/17/2014 2:18:50 PM
Ablynx (ABLYF) To Present Data On Its Anti-Il-6r Nanobody, Developed In Partnership With AbbVie (ABBV), At The American College of Rheumatology Annual Meeting 11/14/2014 10:30:41 AM
Ablynx (ABLYF) Announces Its Business Update For The First Nine Months Of 2014 11/13/2014 10:09:17 AM
Ablynx (ABLYF) To Present Pre-Clinical Proof-Of-Concept Results With Anti-Rsv Nanobody, Alx-0171, At 9th International Respiratory Syncytial Virus Symposium 11/6/2014 7:43:18 AM
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014 6:36:33 AM
12345678910...
//-->